Nihon Bioresearch Inc. is a contract research organization specializing in pharmacological efficacy studies and the development of numerous disease models. This page provides an overview of the company’s non-clinical study capabilities, examples of disease models, and selected study cases. Please use this information as a reference when selecting a CRO for non-clinical studies.
Nihon Bioresearch Inc. has developed more than 300 disease models and evaluation studies are available across a wide range of areas, including pharmaceuticals, medical devices, regenerative medicine products, and functional foods.
The company offers study models with high translational correlation to humans, enabling accurate evaluation and supporting drug discovery and development. With various animal species, Nihon Bioresearch provides assessments based on a broad array of pathophysiological models in central nervous, metabolic, inflammation, and other indications.
The company provides a wide range of non-clinical studies using miniature pigs. It is conducted at a specialized GLP-compliant facility that can house up to 178 animals.
Miniature pigs, known for their strong translational correlation to humans, are used for pharmacology, pharmacokinetics, and safety studies in the cardiovascular, urological, allergic, and metabolic indications.
Nihon Bioresearch Inc. offers tailored CNS studies using multiple small-animal models for evaluating dementia, Parkinson’s disease, depression, anxiety, and related disorders. The company has focused particularly on developing cognitive impairment models such as the rotenone intranigral injection Parkinson’s model and the single intracerebroventricular dose α-synuclein model. A wide range of CNS models—including depression/anxiety, schizophrenia, and autism—can be used for drug efficacy assessment and pathophysiological analyses.
No partner CROs were listed.
Nihon Bioresearch Inc. offers a wide selection of animal models across multiple fields (CNS, respiratory/cardiovascular, metabolic, gastrointestinal, allergic, etc.).
The company can provide proposal study design and develop new models based on client needs.
Their strengths include studies using diverse animal species and advanced CNS evaluation protocols such as PCP-induced schizophrenia models, olfactory bulbectomy–induced depression models, and behavioral/functional analyses of genetically engineered animals.
The company operates a dedicated facility capable of housing up to 178 miniature pigs for both breeding and experimental use.
Its track record includes pharmacology studies for cardiovascular, urological, allergic, and metabolic indication, pharmacokinetic studies of topical formulations, skin irritation testing, and repeated-dose toxicity studies.
Nihon Bioresearch Inc. offers study proposal that account for the characteristics and human translatability of miniature pigs.
Nihon Bioresearch Inc. conducts reproductive and developmental toxicity studies, GLP-compliant studies in miniature pigs, adverse effect confirmation study, and testing of specialized medical devices.
The company offers models with various animal species and administration routes. They have experience performing all ICH Study 1, 2, and 3 studies, including those using transdermal administration.
Furthermore, their proprietary GLP/FDA Part 11–compliant preclinical data management system ensures the delivery of highly reliable data.
Nihon Bioresearch Inc. offers reproducible reliable contracted services with co-development and proposal driven approach for pharmaceuticals, medical devices, and regenerative medicine products.
| Address | 6-104 Majima, Fukuju-cho, Hashima-shi, Gifu, Japan |
|---|---|
| Tel | 058-392-6222 |
| Website | https://www.nbr.co.jp/ |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.